About this Journal Submit a Manuscript Table of Contents
ISRN Vascular Medicine
Volume 2012 (2012), Article ID 165653, 9 pages
http://dx.doi.org/10.5402/2012/165653
Review Article

African Americans and Peripheral Arterial Disease: A Review Article

1Center for Health Equity, University of Minnesota Medical School, Minneapolis, MN, USA
2Department of Preventive Medicine and Public Health, University of Kansas Medical School, 1010 N. Kansas St., Suite 1406, Wichita, KS 67214-3199, USA

Received 15 April 2012; Accepted 18 June 2012

Academic Editors: C. Gaetano, B. Hambly, C. Maziere, A. E. Meinders, and C.-C. Wu

Copyright © 2012 Winta Ghidei and Tracie C. Collins. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. B. Rosero, K. Kane, G. P. Clagett, and C. H. Timaran, “A systematic review of the limitations and approaches to improve detection and management of peripheral arterial disease in Hispanics,” Journal of Vascular Surgery, vol. 51, supplement 4, pp. S27–S35, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Selvin and T. P. Erlinger, “Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000,” Circulation, vol. 110, no. 6, pp. 738–743, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. A. B. Newman, K. Sutton-Tyrrell, and L. H. Kuller, “Lower-extremity arterial disease in older hypertensive adults,” Arteriosclerosis and Thrombosis, vol. 13, no. 4, pp. 555–562, 1993. View at Scopus
  4. T. C. Collins, N. J. Petersen, M. Suarez-Almazor, and C. M. Ashton, “The prevalence of peripheral arterial disease in a racially diverse population,” Archives of Internal Medicine, vol. 163, no. 12, pp. 1469–1474, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. T. C. Collins, M. Johnson, W. Henderson, S. F. Khuri, and J. Daley, “Lower extremity nontraumatic amputation among veterans with peripheral arterial disease: is race an independent factor?” Medical Care, vol. 40, supplement 1, pp. I106–I116, 2002. View at Scopus
  6. L. Norgren, W. R. Hiatt, J. A. Dormandy, M. R. Nehler, K. A. Harris, and F. G. R. Fowkes, “Inter-society consensus for the management of peripheral arterial disease (TASC II),” Journal of Vascular Surgery, vol. 45, supplement 1, pp. S5–S67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Selvin, S. Marinopoulos, G. Berkenblit et al., “Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus,” Annals of Internal Medicine, vol. 141, no. 6, pp. 421–431, 2004. View at Scopus
  8. G. J. Hankey, P. E. Norman, and J. W. Eikelboom, “Medical treatment of peripheral arterial disease,” Journal of the American Medical Association, vol. 295, no. 5, pp. 547–553, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. D. E. Jorenby, S. J. Leischow, M. A. Nides et al., “A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation,” New England Journal of Medicine, vol. 340, no. 9, pp. 685–691, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. W. S. Aronow, “Office management of peripheral arterial disease,” American Journal of Medicine, vol. 123, no. 9, pp. 790–792, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Girolami, E. Bernardi, M. H. Prins et al., “Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis,” Archives of Internal Medicine, vol. 159, no. 4, pp. 337–345, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Gonzales, S. I. Rennard, M. Nides et al., “Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial,” Journal of the American Medical Association, vol. 296, no. 1, pp. 47–55, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. http://www.center4research.org/2010/07/drugs-to-quit-smoking-chantix-and-zyban-can-affect-mental-health/.
  14. R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, “10-Year follow-up of intensive glucose control in type 2 diabetes,” New England Journal of Medicine, vol. 359, no. 15, pp. 1577–1589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. T. C. Collins, R. J. Beyth, D. B. Nelson et al., “Process of care and outcomes in patients with peripheral arterial disease,” Journal of General Internal Medicine, vol. 22, no. 7, pp. 942–948, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. H. Madden, P. Tomsik, J. Terchek et al., “Keys to successful diabetes self-management for uninsured patients: social support, observational learning, and turning points: a safety net providers' strategic alliance study,” Journal of the National Medical Association, vol. 103, no. 3, pp. 257–264, 2011. View at Scopus
  17. B. Rahim-Williams, “Beliefs, behaviors, and modifications of type 2 diabetes self-management among African American women,” Journal of the National Medical Association, vol. 103, no. 3, pp. 203–215, 2011. View at Scopus
  18. J. Östergren, P. Sleight, G. Dagenais et al., “Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease,” European Heart Journal, vol. 25, no. 1, pp. 17–24, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. P. S. Mehler, J. R. Coll, R. Estacio, A. Esler, R. W. Schrier, and W. R. Hiatt, “Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes,” Circulation, vol. 107, no. 5, pp. 753–756, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Yusuf, K. K. Teo, J. Pogue et al., “Telmisartan, ramipril, or both in patients at high risk for vascular events,” New England Journal of Medicine, vol. 358, no. 15, pp. 1547–1559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. S. C. Paravastu, D. Mendonca, and A. Da Silva, “Beta blockers for peripheral arterial disease.,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD005508, 2008. View at Scopus
  22. J. Belch, A. MacCuish, I. Campbell et al., “The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.,” British Medical Journal, vol. 337, article a1840, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. F. G. R. Fowkes, J. F. Price, M. C. W. Stewart et al., “Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial,” Journal of the American Medical Association, vol. 303, no. 9, pp. 841–848, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Catalano, G. Born, and R. Peto, “Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial,” Journal of Internal Medicine, vol. 261, no. 3, pp. 276–284, 2007. View at Publisher · View at Google Scholar
  25. J. S. Berger, “Aspirin as preventive therapy in patients with asymptomatic vascular disease,” Journal of the American Medical Association, vol. 303, no. 9, pp. 880–882, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. “Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration,” British Medical Journal, vol. 308, no. 6921, pp. 81–106, 1994, Erratum appears in British Medical Journal, vol. 308, no. 6943, p. 1540, 1994.
  27. M. Gent, “A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE),” The Lancet, vol. 348, no. 9038, pp. 1329–1339, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Norgren, “New international consensus document on peripheral arterial disease. TASC II for improved care,” Lakartidningen, vol. 104, no. 19, pp. 1474–1475, 2007. View at Scopus
  29. R. Collins, J. Armitage, S. Parish, P. Sleight, and R. Peto, “MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial,” The Lancet, vol. 360, no. 9326, pp. 7–22, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. M. M. McDermott, L. Fried, E. Simonsick, S. Ling, and J. M. Guralnik, “Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: the women's health and aging study,” Circulation, vol. 101, no. 9, pp. 1007–1012, 2000. View at Scopus
  31. S. L. Eason, N. J. Petersen, M. Suarez-Almazor, B. Davis, and T. C. Collins, “Diabetes mellitus, smoking, and the risk for asymptomatic peripheral arterial disease: whom should we screen?” Journal of the American Board of Family Practice, vol. 18, no. 5, pp. 355–361, 2005. View at Scopus
  32. D. C. Gey, E. P. Lesho, J. Manngold, and D. C. Gey, “Management of peripheral arterial disease,” American Family Physician, vol. 69, no. 3, pp. 525–532, 2004. View at Scopus
  33. C. Rucker-Whitaker, P. Greenland, K. Liu et al., “Peripheral arterial disease in African Americans: clinical characteristics, leg symptoms, and lower extremity functioning,” Journal of the American Geriatrics Society, vol. 52, no. 6, pp. 922–930, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. D. L. Dawson, B. S. Cutler, M. H. Meissner, and D. E. Strandness, “Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double- blind trial,” Circulation, vol. 98, no. 7, pp. 678–686, 1998. View at Scopus
  35. J. G. Regensteiner, J. E. Ware, W. J. McCarthy et al., “Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials,” Journal of the American Geriatrics Society, vol. 50, no. 12, pp. 1939–1946, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. E. R. Mohler, W. R. Hiatt, and M. A. Creager, “Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease,” Circulation, vol. 108, no. 12, pp. 1481–1486, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. A. A. Ahimastos, A. Lawler, C. M. Reid, P. A. Blombery, and B. A. Kingwell, “Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease—a randomized trial,” Annals of Internal Medicine, vol. 144, no. 9, pp. 660–664, 2006. View at Scopus
  38. K. J. Stewart, W. R. Hiatt, J. G. Regensteiner, and A. T. Hirsch, “Medical progress: exercise training for claudication,” New England Journal of Medicine, vol. 347, no. 24, pp. 1941–1951, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. M. M. McDermott, S. M. Ohlmiller, K. Liu et al., “Gait alterations associated with walking impairment in people with peripheral arterial disease with and without intermittent claudication,” Journal of the American Geriatrics Society, vol. 49, no. 6, pp. 747–754, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. A. E. Hardman, “Physical activity, obesity and blood lipids,” International Journal of Obesity, vol. 23, supplement 3, pp. S64–S71, 1999. View at Scopus
  41. A. W. Gardner and E. T. Poehlman, “Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis,” Journal of the American Medical Association, vol. 274, no. 12, pp. 975–980, 1995. View at Scopus
  42. W. R. Hiatt, S. Hoag, and R. F. Hamman, “Effect of diagnostic criteria on the prevalence of peripheral arterial disease: the San Luis Valley Diabetes Study,” Circulation, vol. 91, no. 5, pp. 1472–1479, 1995. View at Scopus
  43. W. R. Hiatt, “Medical treatment of peripheral arterial disease and claudication,” New England Journal of Medicine, vol. 344, no. 21, pp. 1608–1621, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. T. C. Collins, S. L. Johnson, and J. Souchek, “Unsupervised walking therapy and atherosclerotic risk-factor management for patients with peripheral arterial disease: a pilot trial,” Annals of Behavioral Medicine, vol. 33, no. 3, pp. 318–324, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. O. A. Larsen and N. A. Lassen, “Effect of daily muscular exercise in patients with intermittent claudication.,” The Lancet, vol. 2, no. 7473, pp. 1093–1096, 1966. View at Scopus
  46. R. B. Patterson, B. Pinto, B. Marcus et al., “Value of a supervised exercise program for the therapy of arterial claudication,” Journal of Vascular Surgery, vol. 25, no. 2, pp. 312–319, 1997. View at Publisher · View at Google Scholar · View at Scopus
  47. J. G. Regensteiner, T. J. Meyer, W. C. Krupski, L. S. Cranford, and W. R. Hiatt, “Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease,” Angiology, vol. 48, no. 4, pp. 291–300, 1997. View at Scopus
  48. P. Savage, M. A. Ricci, M. Lynn et al., “Effects of home versus supervised exercise for patients with intermittent claudication,” Journal of Cardiopulmonary Rehabilitation, vol. 21, no. 3, pp. 152–157, 2001. View at Scopus
  49. A. W. Gardner, D. E. Parker, P. S. Montgomery, K. J. Scott, and S. M. Blevins, “Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial,” Circulation, vol. 123, no. 5, pp. 491–498, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. T. C. Collins, S. Lunos, T. Carlson, et al., “Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral arterial disease: a randomized controlled trial,” Diabetes Care, vol. 34, no. 10, pp. 2174–2179, 2011. View at Publisher · View at Google Scholar
  51. S. J. Marshall, D. A. Jones, B. E. Ainsworth, J. P. Reis, S. S. Levy, and C. A. Macera, “Race/ethnicity, social class, and leisure-time physical inactivity,” Medicine and Science in Sports and Exercise, vol. 39, no. 1, pp. 44–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. C. K. Martin, T. S. Church, A. M. Thompson, C. P. Earnest, and S. N. Blair, “Exercise dose and quality of life,” Archives of Internal Medicine, vol. 169, no. 3, pp. 269–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. G. M. Morss, A. N. Jordan, J. S. Skinner et al., “Dose-response to exercise in women aged 45–75 yr (DREW): design and Rationale,” Medicine and Science in Sports and Exercise, vol. 36, no. 2, pp. 336–344, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. I. M. Lee, L. Djoussé, H. D. Sesso, L. Wang, and J. E. Buring, “Physical activity and weight gain prevention,” Journal of the American Medical Association, vol. 303, no. 12, pp. 1173–1179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. P. M. Dubbert, M. C. Morey, K. A. Kirchner, E. F. Meydrech, and K. Grothe, “Counseling for home-based walking and strength exercise in older primary care patients,” Archives of Internal Medicine, vol. 168, no. 9, pp. 979–986, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. E. J. Tan, Q.-L. Xue, T. Li, M. C. Carlson, and L. P. Fried, “Volunteering: a physical activity intervention for older adults—the experience corps program in Baltimore,” Journal of Urban Health, vol. 83, no. 83, pp. 954–964, 2006. View at Publisher · View at Google Scholar
  57. E. M. Phillips, J. Katula, M. E. Miller et al., “Interruption of physical activity because of illness in the lifestyle interventions and independence for elders pilot trial,” Journal of Aging and Physical Activity, vol. 18, no. 1, pp. 61–74, 2010. View at Scopus
  58. “Experience Corps (EC) Program,” 2011.
  59. A. H. Auchincloss, A. V. Diez Roux, M. S. Mujahid, M. Shen, A. G. Bertoni, and M. R. Carnethon, “Neighborhood resources for physical activity and healthy foods and incidence of type 2 diabetes mellitus: the multi-ethnic study of atherosclerosis,” Archives of Internal Medicine, vol. 169, no. 18, pp. 1698–1704, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. A. E. Mathews, S. B. Laditka, J. N. Laditka et al., “Older adults' perceived physical activity enablers and barriers: a multicultural perspective,” Journal of Aging and Physical Activity, vol. 18, no. 2, pp. 119–140, 2010. View at Scopus
  61. M. Bopp, S. Wilcox, M. Laken et al., “Factors associated with physical activity among African-American men and women,” American Journal of Preventive Medicine, vol. 30, no. 4, pp. 340–346, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Bopp, D. Lattimore, S. Wilcox et al., “Understanding physical activity participation in members of an African American church: a qualitative study,” Health Education Research, vol. 22, no. 6, pp. 815–826, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. N. A. Gallagher, K. A. Gretebeck, J. C. Robinson, E. R. Torres, S. L. Murphy, and K. K. Martyn, “Neighborhood factors relevant for walking in older, Urban, African American adults,” Journal of Aging and Physical Activity, vol. 18, no. 1, pp. 99–115, 2010. View at Scopus